IMiDs New and Old

AbstractPurpose of ReviewIMiDs are a class of biologic agents with immunomodulatory, anti-angiogenic, and direct anti-cancer activities. This review summarizes current data on clinical development and application of IMiDs in non-Hodgkin lymphoma (NHL) subtypes, focusing primarily on lenalidomide, with additional discussion on managing common side effects.Recent FindingsImproved upon the prototype thalidomide, the second-generation compound lenalidomide has enhanced immunological and anti-cancer properties with fewer side effects, while next-generation small molecule cereblon/E3 ubiquitin ligase modulator CC-122 is in early clinical studies. Lenalidomide is FDA-approved for treatment of relapsed/refractory mantle cell lymphoma as a single agent, as well as in combination with rituximab for R/R follicular lymphoma and marginal zone lymphoma. In addition, numerous clinical trials of lenalidomide, as single agent, in combination with anti-CD20 antibodies, or in combination with chemoimmunotherapy regimens, have shown promise in aggressive and indolent NHL in both the upfront and relapsed/refractory setting.SummaryAs clinical trials with lenalidomide continue to find success in both indolent and aggressive lymphomas, IMiDs are poised to be important building blocks for combinatorial strategies with antibodies, chemotherapy, novel target agents, and emerging immunotherapy involving immune checkpoint inhibitors and chimeric antigen receptor T cell (CAR-T) therapy. Delineation of tre...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research

Related Links:

The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study. Material and methods: Analyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer di...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Abstract BACKGROUND: A cohort of male lead-exposed workers with past blood lead levels, previously followed for mortality over 12 years, has now been followed for an additional 10 years. This has doubled the number of deaths and allowed for examination of mortality outcomes across a wide range of blood lead levels. OBJECTIVE: Evaluate association between lead exposure and 16 causes of death. METHODS: The cohort included male workers from 11 U.S. states enrolled in a U.S. lead surveillance program. Maximum blood lead level for each worker was abstracted from surveillance records. Mortality was assessed us...
Source: Environmental Research - Category: Environmental Health Authors: Tags: Environ Res Source Type: research
Researchers call for genetic testing of all survivors of pediatric non-Hodgkin lymphoma after data revealed BRCA2 is implicated in the childhood disease.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population.MethodsA total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis.ResultsThe pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance over time was main...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population. METHODS: A total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis. RESULTS: The pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance ov...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Pharmacokinet Source Type: research
Publication date: Available online 26 June 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Amy A. Ayers, Lin Lyu, Kaylin Dance, Kevin C. Ward, Christopher R. Flowers, Jean L. Koff, Lauren E. McCulloughAbstractBackgroundRacial disparities in non-Hodgkin lymphoma (NHL) are not well elucidated for specific catchment areas, which can influence outcomes. Leveraging regional data from a population-based cancer registry may provide unique opportunities to quantify NHL disparities.MethodsUsing Surveillance, Epidemiology and End Results (SEER) data for NHL cases diagnosed in Georgia from 2001 to 2015, we examined NHL i...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
​BY ANGEL BERMUDEZ, MD, &WESLEY EILBERT, MDAn 81-year-old woman with a history of metastatic lung cancer, hypertension, and COPD presented with dizziness that she described as lightheadedness, generalized weakness, and mild shortness of breath for three days. She also reported recent anorexia and a sensation of impending loss of consciousness.She was thin and appeared ill, and she was unable to stand unsupported. She was afebrile with a heart rate of 101 bpm and a blood pressure of 92/55 mm Hg.Her initial ECG is shown. What else could this be if not ST-elevation myocardial infarction?Our patient was found to have a s...
Source: The Case Files - Category: Emergency Medicine Tags: Blog Posts Source Type: research
Cadherins switching is a hallmark of neoplasic processes. The E-cadherin (E-cad) subtype is one of the surface molecules regulating cell-to-cell adhesion. After its cleavage by sheddases, a soluble fragment (sE-cad) is released that has been identified as a pro-carcinogenic inflammatory signal in several bacteria-induced cancers. Recently we reported that Q fever, a disease due to Coxiella burnetii infection, can be complicated by occurrence of non-Hodgkin lymphoma (NHL). Therefore, we studied E-cad switching in Q fever. The sE-cad levels were found increased in the sera of acute and persistent Q fever patients, whereas th...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
AbstractPurpose of ReviewMantle cell lymphoma is a CD5+ non-Hodgkin lymphoma associated with suboptimal outcome. Young, fit patients are generally offered intensive induction followed by autologous hematopoietic cell transplantation (AHCT) in first remission. Some patients may not benefit from this strategy.Recent FindingsRecent studies have investigated the role of AHCT in the modern era. First, an analysis of the National Cancer Database demonstrated improved progression-free survival (PFS) for consolidative AHCT. Second, a multi-center study associated consolidative AHCT with improved PFS even after propensity-weighted ...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Lymphomas are the heterogeneous group of malignant diseases characterized by proliferation of malignant lymphoid cells or their precursors. Lymphomas are the ninth most common cancer worldwide and constitute 3.2% of malignant tumor. Lymphomas are generally classified to two main categories: Hodgkin's lymphomas (HL) and the non-Hodgkin lymphomas (NHL), and about 90% are NHL. Non-Hodgkin lymphoma represents 4.3% of all new cancer cases in the U.S. and the ninth most common cancer in male patient of Taiwan.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: #25 Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Hematology | Hodgkin's Disease | Immunotherapy | Lymphoma | Non-Hodgkin's Lymphoma | Revlimid | Rituxan | Study